Human Interferon gamma ELISPOT Kit (Reagents for 10 x 96 tests, without plates) (ab46604)
- Datasheet
- References
- Protocols
Overview
-
Product name
Human Interferon gamma ELISPOT Kit (Reagents for 10 x 96 tests, without plates)
See all Interferon gamma kits -
Sample type
Cell culture supernatant, Cell culture extracts -
Assay type
Sandwich (qualitative) -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Intended use
This ELISPOT assay is designed to measure cytokine producing cells in a single cell suspension. This method has the advantage of requiring a minimum of in-vitro manipulations allowing cytokine production analysis as close as possible to in-vivo conditions in a highly specific way. This technique is designed to determine the frequency of cytokine producing cells under a given stimulation, and the follow-up of such frequency during a treatment and/or a pathological state. This Elispot assay constitutes an ideal tool in the TH1 / TH2 response, vaccine development, viral infection monitoring and treatment, oncology, infectious diseases, autoimmune diseases and transplantation.
The Interferon gamma Elispot assay is based on sandwich immuno-enzyme technology. Cell secreted cytokines or soluble molecules are captured by coated antibodies avoiding diffusion in supernatant, protease degradation or binding on soluble membrane receptors. After cell removal, the captured cytokines are revealed by tracer antibodies and appropriate conjugates.
Principle of the method
After cell stimulation, locally produced cytokines are captured by a specific monoclonal antibody. After cell lysis, trapped cytokine molecules are revealed by a secondary biotinylated detection antibody, which is in turn recognised by streptavidin conjugated to alkaline phosphatase. PVDF-bottomed-well plates are then incubated with BCIP/NBT substrate. Colored "purple" spots indicate cytokine production by individual cells.
Recognizes natural human Interferon gamma
-
Tested applications
Suitable for: ELISpotmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 10 x 96 tests Biotinylated Human IFNγ Detection Antibody 2 vials Human IFN Gamma Capture antibody 2 x 0.5ml -
Research areas
-
Function
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. -
Tissue specificity
Released primarily from activated T lymphocytes. -
Involvement in disease
In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis. -
Sequence similarities
Belongs to the type II (or gamma) interferon family. -
Post-translational
modificationsProteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- IF 1
- IFG
- IFI
see all -
Database links
- Entrez Gene: 3458 Human
- Omim: 147570 Human
- SwissProt: P01579 Human
- Unigene: 856 Human
Applications
Our Abpromise guarantee covers the use of ab46604 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISpot |
Optimal dilutions/concentrations should be determined by the end user.
References
ab46604 has not yet been referenced specifically in any publications.
